Xenon Pharmaceuticals Inc (XENE) — Cash Flow-to-Debt Ratio
Xenon Pharmaceuticals Inc (XENE) has a Cash Flow-to-Debt Ratio of -0.20x as of December 2025, meaning its operating cash flow of $-81.48 Million could theoretically repay 0% of its total liabilities ($399.91 Million) in one year. See financial agility of Xenon Pharmaceuticals Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Xenon Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Xenon Pharmaceuticals Inc across 14 annual periods. For the full cash flow conversion analysis, see Xenon Pharmaceuticals Inc operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for Xenon Pharmaceuticals Inc (2012–2025)
Year-by-year debt coverage analysis for Xenon Pharmaceuticals Inc. Check XENE operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.70x | $-279.12 Million | $399.91 Million | ▲ +83.4% |
| 2024 | -4.20x | $-181.39 Million | $43.24 Million | ▼ -6.5% |
| 2023 | -3.94x | $-145.33 Million | $36.88 Million | ▼ -30.7% |
| 2022 | -3.01x | $-98.43 Million | $32.65 Million | ▲ +4.7% |
| 2021 | -3.16x | $-69.50 Million | $21.97 Million | ▼ -17.2% |
| 2020 | -2.70x | $-48.12 Million | $17.83 Million | ▼ -3146.6% |
| 2019 | -0.08x | $-4.63 Million | $55.72 Million | ▲ +95.4% |
| 2018 | -1.81x | $-34.72 Million | $19.13 Million | ▲ +35.6% |
| 2017 | -2.82x | $-28.73 Million | $10.19 Million | ▲ +48.3% |
| 2016 | -5.46x | $-19.57 Million | $3.59 Million | ▲ +12.1% |
| 2015 | -6.21x | $-18.10 Million | $2.92 Million | ▼ -34277.6% |
| 2014 | 0.02x | $266.00K | $14.64 Million | ▲ +116.6% |
| 2013 | -0.11x | $-3.32 Million | $30.37 Million | ▼ -112.2% |
| 2012 | 0.90x | $45.57 Million | $50.68 Million | — |